[Driving fitness/driving capacity of patients treated with methadone]
- PMID: 9816613
[Driving fitness/driving capacity of patients treated with methadone]
Abstract
To answer the question whether or not therapeutic methadone doses significantly reduce traffic-related performance of drivers on medically supervised methadone programmes, 34 methadone substitution patients, all of them volunteers, were subjected to a test series: the focus of the study was a psychophysical test battery consisting of 10 individual performance tests to assess essential functions with regard to driving ability, such as concentration, attention, reaction capability, memory, perception and sensorimotor coordination. In evaluating the results of the psychophysical tests, multiple drug use and subjective methadone influence at the time of the examination were taken into consideration but current methadone blood level was neglected. The results were compared to those of a control group. The methadone group (n = 34) consisted of 25 men and 9 women aged between 18 and 38. At the time of the study, the majority of the test persons (29) were on low dosage methadone maintenance (up to 60 mg/day). In the urine samples of approximately 2/3 of the test persons, evidence was found for multiple drug use together with other psychotropic substances, the most frequent (14) being cannabis metabolites. Referring to their driving practices, a mere 4 out of 29 drivers had not committed any driving offences. A comparison of the psychophysical performance of the whole methadone group (n = 34) with a control group demonstrated that the methadone substitution patients achieved rather lower results in almost all variables. These performance deficits were particularly conspicuous in sustained attention, sensorimotor coordination and reaction capability. 12 "methadone only" participants, i.e. methadone probands without any additional consumption of psychotropic substances showed-partly considerably-better performance than the methadone group as a whole and also achieved normal results in relation to the test norm. Nevertheless, once again, results tended to be of lower level in comparison to the control group. "Methadone only" substitution patients, in particular those volunteers without a current subjective methadone influence-reached practically the same results as the corresponding control subjects, or at least average results based on test norm. However, the study revealed distinctive performance impairment (e.g. in sustained attention, reaction capability) when other psychotropic substances (including alcohol and cannabis!) were taken as well during the subjective methadone phase. The performance deficits were predominantly caused by a slowing down of reactions. Our study illustrates that, under certain conditions, long-term methadone maintenance under strict medical supervision does not have any significant unfavourable impact on the psychophysical performances in driving ability as examined in this study. Thus, these research findings support the previous Zurich experiences, according to which driving ability--and in the end also driving aptitude--of the methadone substitution patients does not depend on the methadone therapy itself, nor on the amount of the daily methadone intake. In making the final medical judgement on driving ability, the presence of a mixed drug use and the personality of the person in question are of far greater importance.
Similar articles
-
[Empirical studies of automobile driving fitness of patients treated with methadone-substitution].Blutalkohol. 1993 Nov;30(6):321-33. Blutalkohol. 1993. PMID: 8292292 German.
-
Influence of peak and trough levels of opioid maintenance therapy on driving aptitude.Eur Addict Res. 2007;13(3):127-35. doi: 10.1159/000101548. Eur Addict Res. 2007. PMID: 17570908 Clinical Trial.
-
[The German promille law--overview and guideline for legal traffic applications].Blutalkohol. 1996 Jul;33(4):177-200. Blutalkohol. 1996. PMID: 8924272 German.
-
Antidepressants and driver impairment: empirical evidence from a standard on-the-road test.J Clin Psychiatry. 2003 Jan;64(1):20-9. J Clin Psychiatry. 2003. PMID: 12590619 Review.
-
Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.Food Chem Toxicol. 2008 Mar;46 Suppl 1:S2-70. doi: 10.1016/j.fct.2008.02.008. Epub 2008 Feb 13. Food Chem Toxicol. 2008. PMID: 18328408 Review.
Cited by
-
Methadone: applied pharmacology and use as adjunctive treatment in chronic pain.Postgrad Med J. 2004 Nov;80(949):654-9. doi: 10.1136/pgmj.2004.022988. Postgrad Med J. 2004. PMID: 15537850 Free PMC article. Review.
-
Effect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine.Br J Clin Pharmacol. 2000 Sep;50(3):237-46. doi: 10.1046/j.1365-2125.2000.00226.x. Br J Clin Pharmacol. 2000. PMID: 10971308 Free PMC article. Clinical Trial.
-
Multiple-Dose Pharmacokinetics and Safety of Mitragynine, the Major Alkaloid of Kratom, in Rats.ACS Pharmacol Transl Sci. 2024 Jul 25;7(8):2452-2464. doi: 10.1021/acsptsci.4c00277. eCollection 2024 Aug 9. ACS Pharmacol Transl Sci. 2024. PMID: 39144552 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical